科達利(002850.SZ):擬將部分募集資金借款轉爲對全資子公司增資
格隆匯6月30日丨科達利(002850.SZ)公佈,公司於2025年6月30日召開第五屆董事會第二十次(臨時)會議及第五屆監事會第十一次(臨時)會議審議通過了《關於將部分募集資金借款轉爲對全資子公司江西科達利等增資的議案》,同意公司將2023年向特定對象發行股票募集資金前期分別向全資子公司江西科達利精密工業有限公司(以下簡稱“江西科達利”)、湖北科達利精密工業有限公司(以下簡稱“湖北科達利”)、江門科達利精密工業有限公司(以下簡稱“江門科達利”)提供的部分借款及後續擬投入的部分募集資金轉爲對其增資。本次增資完成後,上述子公司仍爲公司的全資子公司。該議案無需提交至股東會審議批準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.